Skip to main content
Equibles
DTIL logo

DTIL · Precision Biosciences Inc

Track DTIL — free

Use DTIL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DTIL

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.85 +0.13 (+1.49%) At close · Aug 21
Market Cap
$240.69M
Shares
27.60M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.85 Open$8.81 Day$8.63–9.08 52W close$3.57–9.28 Avg vol 30d313K Short int2.9M · 10.4% float · 10.5d Short vol44% Last earningsFeb 11, 2026 DataFeb 2024–Aug 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Feb 14, 2024; bars on opposite sides are not compared.

Up next

FQ2-27 quarter ends
~Nov 21, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +46%
above
Price vs 50-day avg +17%
above
RSI (14) 72
overbought
MACD trend Positive
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +21%
trailing
6-month return +104%
trailing
YTD return +113%
this year
Relative strength +93%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+22% holders QoQ · +30 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.43% of float · ▲ +20.7% MoM · 10.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
95 holders — near 3-yr high, broad support
Squeeze score 98
high risk · 0–100
Fundamentals
Fair
EPS growth −442%
Y/Y
Balance sheet $88.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −59%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 7, 2025
Reduction in annual cash operating expenses · each of 2026 and 2027 up to $25M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+46% Bullish
Price vs 50-day avg
+17% Bullish
RSI (14)
72 Bearish
MACD trend
Positive Bullish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+22% holders QoQ · +30 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.43% of float · ▲ +20.7% MoM · 10.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
95 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $9 · 92% Range high $9
vs 200-day avg +46% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash balance including cash, cash equivalents and restricted cash 112.4M As of June 30, 2026 —
cash raised $75M November 2025 —
patients dosed across first 5 cohorts of ELIMINATE-B trial 13 to date (as of report date) —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DTIL
Precision Biosciences Inc
this stock
$240.69M +112.7% +41.0% — 10.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +20.9% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.56B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
95
% held
64.1%
Net QoQ
+1.5M sh
Top holder
Aberdeen Group plc
Held Float
View
Held by Funds
Fund positions
34
View
Short & Settlement
Short Interest Rising
Shares short
2.9M
Days to cover
10.5d
Change
+493.8K sh
View
Short Volume
Short vol %
44%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
3.1K
Value
$21.7K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
46.2%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$34.3M
Net income (FY)
$-45.7M
EPS diluted
$-3.56
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
16
View
Proposed Sales
Value
$79.0K
Shares
20.6K
Filed
Feb 18, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 3, 2026
View

Performance

Raw-price comparisons begin at the captured split on Feb 14, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
DTIL +19.1% +21.4% +104.4% +26.6% +112.7%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +20.5% +17.8% +92.8% +24.1% +100.5%
Key facts CIK 1357874 CUSIP 74019P207 13F (30d) 92 filings 91 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)